Related by context. All words. (Click for frequent words.) 73 lymphomas 72 non Hodgkin lymphomas 71 cell lymphoma 71 cell malignancies 70 cell lymphoma DLBCL 68 cell acute lymphoblastic 66 leukemias 66 DLBCL 66 malignancies 65 B lymphocytes 65 cell lymphoma ALCL 64 follicular lymphoma 64 cell lymphoma PTCL 64 leukemia CLL 64 myeloproliferative diseases 64 hepatocellular carcinoma HCC 64 epithelial tumors 64 cell lymphoma CTCL 63 medulloblastomas 63 suppressor cells 63 neuroendocrine tumors 63 Follicular lymphoma 63 chronic lymphocytic leukemia CLL 63 cell chronic lymphocytic 62 adenocarcinomas 62 myeloma cells 62 leukemia AML 62 hematologic malignancies 62 neoplastic 62 myeloproliferative 62 breast carcinomas 62 leukemia ALL 62 subtypes 62 lymphoma subtypes 62 lymphoid 61 multiple myeloma MM 61 medullary thyroid cancer 61 Epratuzumab 61 leukaemias 61 solid tumors 61 pheochromocytoma 61 myeloproliferative neoplasms 61 CD# mAb 61 B CLL 61 epithelial cancers 61 Non Hodgkin lymphoma 61 myelofibrosis polycythemia vera 61 effector T 61 Cell Non Hodgkin 61 subtype 60 ovarian carcinoma 60 myeloid 60 imatinib resistant 60 renal cell carcinoma 60 lymphoproliferative disorders 60 T#I mutant 60 activating mutations 60 lymphoid organs 60 relapsed refractory 60 SSc patients 60 mycosis fungoides 60 Lymphomas 60 IL 1ß 60 CD# [002] 60 Gleevec resistant 60 CLL SLL 60 lymphoid tissue 60 V#F mutation 60 FLT3 60 androgen receptor AR 60 histologies 60 MGUS 60 EGFRvIII 60 neuroblastomas 60 pediatric acute lymphoblastic 60 small lymphocytic lymphoma 59 myeloproliferative disorders 59 cholangiocarcinoma 59 HCV infection 59 activin 59 T#I [002] 59 mutated KRAS gene 59 hematologic disorders 59 cancers 59 cutaneous T 59 EGFR inhibitors 59 NKT cells 59 ccRCC 59 tumor metastases 59 medulloblastoma 59 EGFR mutations 59 MALT lymphoma 59 CLL cells 59 HNSCC 59 osteoclast 59 squamous cell carcinoma SCC 59 CD# antigen 59 CLL 59 hematological cancers 59 Diffuse Large B 59 autoimmunity 59 effector function 59 systemic lupus erythematosus SLE 59 JAK2 mutation 59 acute leukemias 59 HCV infections 59 CD8 + 59 chronic myeloid leukemia CML 59 indolent NHL 59 essential thrombocythemia 59 chronic HBV infection 59 TNF α 59 Sezary syndrome 59 depsipeptide 58 K ras 58 malignant neoplasms 58 bladder cancers 58 carcinoid tumors 58 K ras mutations 58 gastric carcinoma 58 squamous cell carcinomas 58 leukemic stem cells 58 imatinib Gleevec 58 HDACi 58 JAK3 58 Acute lymphoblastic leukemia 58 peripheral blood mononuclear 58 carcinoid 58 papillary 58 Cutaneous T 58 cell carcinoma 58 familial amyloidotic polyneuropathy FAP 58 lymphoid malignancies 58 hypermethylation 58 CTCL 58 mesotheliomas 58 T lymphocytes 58 SSc 58 lymphocytosis 58 oncoproteins 58 hematological malignancies 58 relapsed leukemia 58 carcinomas 58 hypereosinophilic syndrome 58 hepatocellular carcinoma 58 lymphocytes 58 lymphocytic 58 receptor subtype 58 neuroendocrine cancers 58 lymphocyte 58 epithelioid 58 pancreatic adenocarcinoma 58 B lymphocyte 58 SCCHN 58 sporadic ALS 58 neoplasms 58 GISTs 58 pulmonary metastases 58 germinal center 58 autoimmune diseases 58 non Hodgkin lymphoma 58 E#F# 58 Non Hodgkin Lymphoma 58 Leukemias 58 chronic myelogenous leukemia CML 58 Treg cells 58 EpCAM 58 Aurora kinases 58 prostate cancer CaP 58 paragangliomas 57 lung carcinomas 57 lymphoid cells 57 glioma cells 57 common hematologic malignancy 57 autoreactive T cells 57 proto oncogene 57 NSCLC 57 sarcomas 57 cutaneous T cell 57 MAPK pathway 57 Epstein Barr virus EBV 57 Chronic Lymphocytic Leukemia CLL 57 neuroblastoma cells 57 HER2/neu 57 KRAS mutant 57 renal cell carcinomas 57 Metastatic 57 interleukins 57 Epidermal Growth Factor Receptor 57 proteasome inhibitor 57 leukemic cells 57 imatinib resistance 57 Hodgkin lymphoma HL 57 CYT# potent vascular disrupting 57 Telintra 57 histological subtype 57 missense mutations 57 carcinoma 57 SOD1 57 pan HDAC inhibitor 57 glioblastoma 57 hepatocellular carcinomas 57 diabetic nephropathy 57 gastric cancers 57 urothelial carcinoma 57 interferon IFN 57 HBeAg positive 57 gastrointestinal stromal tumors GISTs 57 chemotherapy induced neutropenia 57 premalignant 57 IGF IR 57 chemokine receptors 57 Foxp3 57 apoptotic pathway 57 basal cell carcinoma BCC 57 Plasmodium falciparum 57 myeloid cells 57 blinatumomab 57 skeletal metastases 57 basal cell carcinomas 57 hypoxia inducible factor 57 IGF 1R 57 haematological malignancies 57 BRAF mutations 57 tumoral 57 targeting CD# 57 sarcomatoid 57 HBeAg negative 57 neurokinin 57 alkylating agent 57 Staphylococcus aureus infections 57 systemic lupus erythematosus 57 CD4 + CD# 57 lupus nephritis 57 JAK inhibitors 57 oncogenic 57 cytotoxin 57 clade B 57 effector memory 57 Raf MEK ERK 57 NF kB pathway 57 Gliomas 57 histologic subtype 57 cell epitopes 57 EGFR mutation 57 activated lymphocytes 57 TTR gene 57 papillary RCC 56 JAK2 enzyme 56 FGFR2 56 mTOR inhibitors 56 oncogenes 56 effector cells 56 pancreatic cancers 56 VEGF receptor 56 prostate pancreatic 56 EGFr 56 colorectal tumors 56 breast carcinoma 56 serous ovarian cancer 56 Glioblastoma Multiforme 56 HLA DR 56 bleomycin 56 GBMs 56 lymphoma CTCL 56 Chronic lymphocytic leukemia CLL 56 VEGF inhibitors 56 cells hESCs 56 EGF receptor 56 mucinous 56 glioblastomas 56 HBV genotypes 56 Carcinoid tumors 56 hepatoma 56 myelodysplastic syndrome MDS 56 castration resistant prostate cancer 56 neoplasm 56 Vidofludimus 56 leukemia CML 56 osteosarcomas 56 posaconazole 56 Mantle Cell Lymphoma 56 castrate resistant prostate cancer 56 HuMax CD4 56 ERK1 2 56 BRAF V#E 56 Toxicities 56 HTLV 56 cell lymphoblastic lymphoma 56 gastrointestinal stromal tumor GIST 56 immunopathology 56 ADAM# 56 GNAQ 56 JAK2 56 node metastases 56 mediated immunity 56 TTR amyloidosis 56 Treg cell 56 chemoresistance 56 Chronic lymphocytic leukemia 56 mediated autoimmune diseases 56 imatinib Gleevec ® 56 herpesviruses 56 Hedgehog pathway 56 CXCR4 56 basal cell nevus syndrome 56 mutational status 56 xenograft models 56 Th2 cells 56 superficial bladder cancer 56 induce apoptosis 56 tumor xenograft models 56 soft tissue sarcomas 56 serine threonine kinases 56 phosphatases 56 enzastaurin 56 fibrotic disease 56 Th# cells 56 tyrosine kinase inhibitors 56 nonmelanoma skin cancers 56 metastases 56 differentiated thyroid 56 familial ALS 56 induces apoptosis 56 PXD# 56 vimentin 56 gastric adenocarcinoma 56 immune modulators 56 BCL2 56 polycythemia vera PV 56 heavily pretreated 56 Myelodysplastic syndromes MDS 56 pDCs 56 gliomas 56 chronic lymphocytic leukemia 56 hematologic 56 germline mutations 56 Myelofibrosis 56 Aurora kinase 56 bcl 2 56 IMGN# 56 HLA DRB1 * 56 adenocarcinoma 56 lymphoid tumors 56 nonsmall cell lung cancer 56 BCR ABL 56 chronic eosinophilic leukemia 56 ansamycin 56 associated lymphoid tissue 56 EGFR HER2 56 Azedra 56 romidepsin 56 fungoides 56 squamous 56 Th2 56 lymphoblastic leukemia 55 astrocytomas 55 antigen CD# 55 c MYC 55 bendamustine 55 WT1 55 castration resistant 55 uPAR 55 receptor tyrosine kinase inhibitor 55 colorectal carcinoma 55 Systemic lupus erythematosus SLE 55 multiple myeloma 55 retinoic acid receptor 55 castrate resistant 55 brain metastases 55 IgG1 monoclonal antibody 55 actinic keratosis 55 papillary renal cell carcinoma 55 replicon 55 tumor suppressor genes 55 haematopoietic 55 colon carcinoma 55 BRAF mutation 55 Kaposi sarcoma 55 hyperplastic 55 glioblastoma multiforme GBM 55 immune modulator 55 metastatic cancers 55 cancer mCRC 55 Non Hodgkin lymphomas 55 metastatic 55 oncoprotein 55 IFNs 55 malignancy 55 NKG2D 55 GvHD 55 PTPN# 55 Glucocorticoids 55 mediated apoptosis 55 TNF antagonist 55 JMML 55 mononuclear cells 55 lung adenocarcinomas 55 interleukin IL -# 55 Inflammatory bowel diseases 55 lymphoproliferative disorder 55 immune mediated 55 ERBB2 55 malignant transformation 55 receptor antagonists 55 cathepsin B 55 VZV 55 glioblastoma cells 55 FasL 55 lymphocytic leukemia 55 MTHFR 55 Hedgehog signaling pathway 55 bronchial epithelial cells 55 metastatic neuroendocrine tumors 55 cathepsin 55 BRAF gene 55 humanized monoclonal antibody 55 EGFR 55 seminomas 55 synuclein 55 ABCB1 55 lung cancers 55 KRAS wild 55 c MET 55 refractory indolent non 55 syngeneic 55 colorectal adenocarcinoma 55 hTERT 55 proliferative disorders 55 TRAIL induced apoptosis 55 cytotoxic T 55 chronic granulomatous disease 55 histone deacetylase HDAC inhibitor 55 HCV 55 Evoltra ® 55 lysosomal storage diseases 55 Xanafide 55 malignant lymphoma 55 c myc 55 AT1R 55 oncogenic transformation 55 gastrointestinal stromal tumor 55 gastrointestinal stromal tumors 55 PDGF receptor 55 recurrent glioblastoma multiforme 55 deletion 5q 55 erlotinib Tarceva ® 55 mitogen activated protein kinase 55 constitutively active 55 Flt3 55 polycythemia vera 55 PI3K inhibitors 55 astrocytoma 55 staphylococci 55 HbF 55 P. aeruginosa 55 follicular non 55 ovarian lung 55 extranodal 55 liver metastases 55 panobinostat 55 brain tumor glioblastoma multiforme 55 polymerase inhibitors 55 Gorlin syndrome 55 TREANDA 55 follicular lymphoma FL 55 cisplatin resistant 55 VEGFR2 55 IL 1β 55 nucleoside analogues 55 hematopoietic malignancies 55 serogroups 55 IFN gamma 55 homozygotes 55 gastric lymphoma 55 Janus kinase 55 non metastatic osteosarcoma 55 C5aR 55 ovarian tumors 55 metastatic colorectal 55 elacytarabine 55 HBeAg negative chronic hepatitis 55 PCNSL 55 distant metastasis 55 MGd 55 malignant fibrous histiocytoma 55 gene rearrangements 55 CD# molecule 55 Tregs 55 systemic anaplastic large 55 hematological malignancy 55 anticancer therapy 55 T#I mutation 55 HLA B# 54 hematologic cancers 54 hematopoietic cells 54 PARP inhibitors 54 systemic fungal infections 54 acute myelogenous leukemia AML 54 Th1 54 cytomegalovirus CMV 54 CD#b 54 Vorinostat 54 catenin 54 bone metastasis 54 monoclonal 54 EGFR tyrosine kinase inhibitors 54 HER2 receptor 54 EBV infection 54 chemotherapeutic agent 54 hamartomas 54 osteoclast activity 54 PI3K inhibitor 54 belinostat 54 KRAS gene 54 nonsense mutations 54 S. aureus 54 nasopharyngeal carcinoma 54 Th1 cells 54 hematopoietic 54 tumor antigen 54 chromosomal rearrangement 54 ErbB3 54 AEG# 54 anti leukemic 54 superficial basal cell carcinoma 54 KIT mutations 54 hematological diseases 54 Hodgkin lymphoma NHL 54 pleomorphic 54 idiopathic thrombocytopenic purpura ITP 54 decitabine 54 ADPKD 54 eosinophils 54 HGS ETR2 54 JAK2 V#F 54 nonalcoholic steatohepatitis NASH 54 tigecycline 54 prostate cancer PCa 54 metastatic renal cell carcinoma 54 trans retinoic acid 54 granulocytes 54 lobular carcinoma 54 P. gingivalis 54 molecularly targeted 54 autoimmune 54 precursor lesions 54 galiximab 54 Acute myeloid leukemia 54 leiomyoma 54 ErbB2 54 hematopoietic cell 54 CD# monoclonal antibody 54 childhood leukemias 54 Akt 54 vWD 54 cervical carcinoma 54 pRb 54 basal cells 54 invasive candidiasis 54 antibody mediated 54 metastasis 54 extracellular domain 54 Ceflatonin 54 myelofibrosis MF 54 pneumococcal serotypes 54 azacitidine 54 COX2 54 CD# receptor 54 erythropoiesis 54 coagulation cascade 54 anaplastic 54 hematological 54 myelomas 54 54 essential thrombocythemia ET 54 lysosomal 54 metastatic bladder 54 CHOP chemotherapy 54 NOTCH1 54 metastatic colorectal cancer 54 kidney urologic 54 mCRC patients 54 milatuzumab 54 Amrubicin 54 basal cell carcinoma 54 missense mutation 54 HCV genotypes 54 metastatic melanoma 54 ISTODAX 54 oncogenic HPV types 54 grade cervical intraepithelial 54 estrogen receptor beta 54 cell lymphoma MCL 54 PI3K pathway 54 mRCC 54 malignant lymphomas 54 sPLA2 54 HBV genotype 54 anemias 54 Proxinium TM 54 ependymomas 54 PIK3CA 54 CD# expressing 54 MAGE A3 54 HIF PHI 54 HER2 positive metastatic breast 54 aberrantly activated 54 breast pancreatic 54 prostate carcinoma 54 oligodendrogliomas 54 autoimmune disease 54 chemotherapeutic agents 54 cell Lymphoma PTCL 54 neoplasias 54 breast tumors 54 endometrioid 54 immunoreactivity 54 soluble tumor necrosis 54 renal tumors 54 tyrosine kinases 54 tumors 54 MEK inhibitors 54 p# MAP kinase 54 phosphate S1P 54 acute myeloid leukemia AML 54 leukemia APL 54 ependymoma 54 Smad3 54 tumor subtypes 54 T lymphocyte 54 relapsed refractory multiple myeloma 54 NEUVENGE 54 monocyte chemoattractant protein 54 sodium glucose cotransporter 54 NAGS deficiency 54 autoimmune inflammatory 54 Rituximab 54 micrometastases 54 severe malignant osteopetrosis 54 metastatic malignant melanoma 54 viral subtypes 54 thalidomide Thalomid 54 huN# DM1 54 promoter methylation 54 huC# DM4 54 Zolinza 54 myelodysplastic syndromes 54 ras gene 54 JAK inhibitor 54 GBM tumors 54 carcinoids 54 refractory acute myeloid 54 cyclin E 54 PTLD 54 YONDELIS 54 neoplastic cells 54 prognostic marker 54 oncogenesis 54 NS4A 54 glycogen synthase kinase 54 sphingosine 1 54 Enterobacteriaceae 54 colony stimulating factors 54 CagA 54 paraganglioma 54 MYCN amplification 54 AML MDS 54 potent inhibition 54 VEGF 54 p# MAPK 54 MMP inhibitors 54 myelofibrosis 54 Cytotoxic T 54 neoplastic lesions 54 HCV protease 54 lymphoma 54 hepatitis C HCV 54 hyperplasia 54 haematological toxicity 54 cytokine IL 54 antitumor 54 virulence genes 54 LNCaP cells 54 lymphangiogenesis 54 PKC# 54 serogroup 54 Metastatic breast cancer 54 glycosylated 54 HDAC 54 chronic hepatitis 54 kinase inhibition 54 NFκB 54 lung tumors 54 Alemtuzumab 54 cirrhosis liver failure 54 transfected cells 54 Polycythemia vera 54 T2DM 54 anti angiogenic agents 54 poly ADP ribose polymerase 54 brucei 53 carcinoembryonic antigen 53 S1P 53 isotypes 53 clade C 53 receptor tyrosine kinases 53 tumor antigens 53 microRNA miR 53 Clusterin 53 plasma kallikrein 53 xenograft tumors 53 histone deacetylase inhibitor 53 malignant tumors 53 Malignant Melanoma 53 gastrointestinal cancers 53 lymphocyte activation 53 PNH patients 53 tumor cells 53 metastatic lesions 53 metastatic RCC 53 proteasome inhibitors 53 cytotoxic 53 Hashimoto thyroiditis 53 AP# [003] 53 INCB# [003] 53 Glioblastoma multiforme GBM 53 tumor suppressors 53 GSK3B 53 malignant phenotype 53 MDM2 53 Streptococcus pyogenes 53 GSTP1 53 costimulatory 53 caveolin 1 53 N Myc 53 pro angiogenic 53 mesenchymal cell 53 PI3 kinase 53 HER-2/neu 53 premalignant lesions 53 Li Fraumeni Syndrome 53 Sarcomas 53 APOPTONE 53 nutlin 3a 53 PTHrP 53 HDAC inhibitor 53 colorectal cancer CRC 53 hepatocellular cancer 53 thymoma 53 staphylococcal infections 53 interferon alfa 53 transgene expression 53 Symadex 53 antibody MAb 53 survivin 53 rhIL 7 53 dasatinib Sprycel 53 dasatinib Sprycel ® 53 immune dysregulation 53 metastatic tumors 53 PDGFR 53 HGS ETR1 53 acute humoral rejection 53 Aplidin 53 Burkitt lymphoma 53 Valortim R 53 TACI Ig 53 overexpressed 53 FGFR3 53 protein kinases 53 MDR1 53 receptor subtypes 53 Niemann Pick type 53 precursor acute lymphoblastic 53 microglial activation 53 CMV disease 53 MEFs 53 anti angiogenic drugs 53 leukemic cell 53 Kit CD# positive 53 osteoblast 53 BMP2 53 malignant neoplasm 53 humoral 53 CD# CD# 53 serine protease 53 cyclin dependent kinase inhibitor 53 rituximab 53 neuroendocrine carcinoma 53 Bcr Abl 53 monocytes macrophages 53 kinase inhibitor 53 erythroid 53 chemokines 53 IL 1beta 53 PCa 53 Sudhir Agrawal D.Phil 53 ALK inhibitor 53 proteolytic cleavage 53 PNP inhibitor 53 calcineurin inhibitors 53 eculizumab 53 PDE#A 53 CD8 + T 53 Waldenstrom macroglobulinemia 53 PPARgamma 53 superantigens 53 alefacept 53 lymphadenopathy 53 Blinatumomab 53 colon lung 53 selective modulator 53 HDAC inhibitors 53 estrogen receptor ER 53 leukocyte adhesion 53 gefitinib Iressa 53 anaplastic lymphoma kinase 53 histiocytes 53 TNF blocker therapy 53 cytopenias 53 iNOS 53 PAR1 53 invasive fungal infections 53 cathepsins 53 herpes zoster shingles 53 papillomas 53 JAK1 53 plasmacytoid dendritic cells 53 idiopathic myelofibrosis 53 Escherichia coli Klebsiella pneumoniae 53 chlamydial 53 metastatic cancer 53 malignant pleural mesothelioma 53 hA# 53 Cholangiocarcinoma 53 pDC 53 sodium thiosulfate STS 53 ALCL 53 phosphorylate 53 tyrosine kinase inhibitors TKIs 53 ERK signaling 53 CD# + [001] 53 erythrocytes 53 Acute Myeloid Leukemia AML 53 RANK ligand 53 KRAS mutations 53 tyrosine kinase 53 PARP inhibition 53 TGF beta 53 relapsed indolent 53 relapsed acute myelogenous 53 autoantibodies 53 herpes viruses 53 candidemia 53 squamous cell cancers 53 humanized antibody 53 HepG2 cells 53 gastric cancer 53 beta thalassemia 53 IV administered darinaparsin 53 acute coronary syndromes ACS 53 inducible nitric oxide synthase 53 PC3 cells 53 TRIOLEX 53 interferon γ 53 recurrent NSCLC 53 constitutively activated 53 MKC# MT 53 immunodeficiency 53 rituximab Rituxan 53 antisense inhibitors 53 N. gonorrhoeae 53 mitochondrial toxicity 53 protein tyrosine phosphatases 53 secondary hyperparathyroidism 53 PPAR γ 53 relapsed MM 53 Niemann Pick disease 53 renal fibrosis 53 neurological manifestations 53 lysosomal storage disease 53 selective inhibition 53 C. albicans 53 epithelial ovarian 53 HGF 53 elotuzumab 53 Metastasis 53 cytotoxic agents 53 metastatic melanomas 53 VEGF receptors 53 prostate breast 53 clusterin 53 ibritumomab tiuxetan 53 Chronic Lymphocytic Leukemia 53 chronic HBV 53 FGFR1 53 HBV 53 factor receptor EGFR 53 intravenous belinostat 53 investigational compounds 53 cell carcinomas 53 DXL# 53 bispecific 53 APOL1 53 mGluR 53 cytochrome P# 53 cytotoxic effects 53 Non Hodgkin Lymphomas 53 Gleevec imatinib mesylate 53 IL #E 53 MPS IVA 53 Trastuzumab 53 HPV# 53 seminoma 53 squamous cell cancer 53 acute promyelocytic leukemia APL 53 CCR9 53 allograft rejection 53 PKCi 53 trabectedin 53 Pathway Inhibitor 53 imatinib therapy 53 synovial sarcoma 53 cervical lymph nodes 53 Vidaza azacitidine 53 Epstein Barr virus 53 B Cell Lymphoma 53 isoenzyme 53 pro apoptotic 53 Hsp# inhibitors 53 prostate cancers 53 refractory CLL 53 multidrug resistance 53 Apaziquone 53 potent inhibitors 53 IFN alpha 53 ENMD # 53 stage IIIB 53 micafungin 53 EGFR protein 53 autoantibody 53 investigational monoclonal antibody 53 proliferative diseases 53 Wnt signaling pathway 53 peritoneal carcinomatosis 53 myelodysplastic syndromes MDS 53 cAMP signaling 53 molecular abnormalities 53 serotonin receptor 53 chronic HCV 53 T Cell Lymphoma 53 murine 53 receptor inhibitor 53 alkylating agents 53 investigational therapies 53 neuroblastoma tumors 53 IGFBP 53 prostaglandin synthesis 53 refractory gout 53 metastatic disease 53 p# mutation 53 ALN TTR 53 TNFalpha 53 cell adhesion molecule 53 pneumoniae 53 BiovaxID 53 EGF receptors 53 invasive ductal 53 NY ESO 53 isoform 53 PAOD 53 pancreatic carcinoma 53 L BLP# 53 chronic GVHD 53 ovarian breast 53 hedgehog pathway 53 hypomethylating agents 53 Plasmodium 53 pancreatic tumors 52 P. falciparum 52 TNFa 52 rs# [004] 52 Factor VIIa 52 kinase inhibitors 52 lysosomal storage disorders 52 Non Hodgkin 52 cytogenetic responses 52 SPINK1 52 cutaneous melanoma 52 Romiplostim 52 GIST tumors 52 Genentech Rituxan 52 refractory NSCLC 52 hepatic stellate cells 52 pro inflammatory cytokines 52 pegylated liposomal doxorubicin 52 Hepatocellular Carcinoma HCC 52 pediatric Crohn disease